Good news related to prx002

[Farooqji]

Interesting in light of the negative results from Biogen’s study of a similar (but not the same) mAb against alpha-synuclein. Roche/Prothena also reported negative results for their primary outcome in the prior study, but encouraging results for secondary outcome measures.

clinicaltrials.gov/ct2/show...

[Parkinsonjisung]

Where are the results posted? I don't see them on the trial site but maybe I'm blind

[Farooqji in reply to Parkinsonjisung]

ir.prothena.com/news-releas...

[Parkinsonjisung in reply to Farooqji]

Thanks. I think there's some more detail being given out at a conference on the 11th

[Farooqji in reply to Parkinsonjisung]

It is yet awaited (expected within march 2021)

[Parkinsonjisung in reply to Farooqji]

Just read the details of the phase 2b they announced. It's a huge trial. Either the secondary outcomes are extremely positive or they're idiots chasing a lost cause.

[mitel]

Biogen purchased a stake in Denali pharmaceuticals both were developing the same anti synuclian drug the Denali drug was already in pill form and crossed the blood brain barrier. Biogens version was injected into the spinal fluid then all of the sudden Biogen stopped the trail, my opinion they were developing the same drug Denli was farther along already in pill form.

[amykp]

I can't seem to get it to open. What are they saying? Might someone please summarize? It is funny to me how all these monoclonal antibody studies seem to do so poorly because I feel like they make good sense. Like they ought to work. So this sounds interesting.

But I can't imagine an antibody type drug (from Denali?) ever given in pill form...how would it not be denatured in the stomach?

[Parkinsonjisung in reply to amykp]

They said nothing really other than they're doing a new phase 2b trial. Further data is expected soon. Likely after they present at a conference on the 11th

[amykp in reply to Parkinsonjisung]

Ah, thanks. Still kinda frustrating, no?

[Parkinsonjisung in reply to amykp]

Ya, as I said earlier in the thread the announcement of the phase 2b doesn't make a whole lot of sense unless there was something extremely convincing in the secondary outcome. Let's wait and see.

[sharoncrayn in reply to Parkinsonjisung]

"the study did not meet the primary objective, but showed signals of efficacy."

In plain English, It failed to meet minimal UPDRS 1,2,3 level efficacy changes which is unbelievable.

Any patient who medically required initiation of dopaminergic therapy during Part 1 have had their subsequent data censored for the primary endpoint analysis. Really?

Part 2 is "on hold" due to covid.

[sharoncrayn]

"but encouraging results for secondary outcome measures."

they don't specify what they are.